BioSpace News Archive

Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), is pleased to report that the first subjects have been randomized and dosed in the United States (U.S.) in the PARA_OA_002 pivotal clinical trial, evaluating injectable pentosan polysulfate sodium (PPS/Zilosul®) for the treatment of pain associated with knee osteoarthritis (kOA).

BioSystics, Inc. , a recent spin-off from the University of Pittsburgh (UPitt), has been developing the Microphysiology Systems Database, the core of the BioSystics Analytics Platform (BioSystics-AP™), with funding over the last ten years from the National Center for Advancing Translational Sciences (NCATS).

Labcorp, a leading global life sciences company, announced that its Annual Meeting of Shareholders will be webcast live beginning May 11, at 9:00 a.m. ET.

The National Academy of Sciences has elected The Feinstein Institutes for Medical Research’s Betty Diamond, MD, in recognition of her breakthrough achievements in molecular medicine and original research.

Amend Surgical, Inc. announced that it has finalized a funding agreement with the Institute for Commercialization of Florida Technology along with being awarded a substantial product development funding from The Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center.

Rhino Biotech Limited, a Biotech Company, announced it will be presenting at the SNN Network Planet MicroCap Showcase on May 4, 2022 at 2:30 p.m. Pacific Time.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported first quarter 2022 financial results and provided a corporate update.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2022.

Rain Therapeutics Inc. reports financial results for the first quarter ended March 31, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.

Societal CDMO, Inc. announced that the company will release financial results for the first quarter 2022 after the market close on Wednesday, May 11, 2022.